|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
Biomarker
|
disease |
BEFREE |
A diagnosis of AML with maturation (AML-M2) and AML1/ETO was made.
|
30921216 |
2019 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of core-binding factor acute myeloid leukemias.
|
27798625 |
2016 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
t(8;21)(q22;q22) giving rise to RUNX1/RUNX1T1 fusion transcript is a recurrent non-random chromosomal translocation, accounting for approximately 5% of cases of acute myeloid leukemia and 10% of acute myeloid leukemia with maturation.
|
19896694 |
2010 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
Biomarker
|
disease |
CTD_human |
Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
|
18206229 |
2008 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Section of Hematology, Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Center has shared this experience during the last 10 years with more than 6,546 samples submitted for the analysis of different gene rearrangements, fusion gene transcripts and gene mutations including Ig heavy chain gene rearrangement for B-cell malignancies, T-cell receptor gamma chain gene rearrangement for T-cell malignancies, BCR/ABL-P210 and P190 fusion gene transcripts, for chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia, PML/RARalpha fusion gene for promyelocytic leukemia, AML1/ETO for acute myeloid leukemia AML-M2 with t8;21, CBFB/MYH11 for AML M4E0 with inv 16, BCL-2 for follicular lymphoma, and BCL-1 for mantle cell lymphoma.
|
16228048 |
2005 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
Biomarker
|
disease |
BEFREE |
The chromosomal translocation t(8;21), generating the AML1-ETO fusion protein, is frequently associated with French-American-British (FAB) type M2 acute myeloid leukemia (AML). t(8;21) fuses the runt domain from the hematopoietic transcription factor RUNX1 with almost the entire transcriptional repressor ETO.
|
16390317 |
2005 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The translocation t(8;21)(q22;q22), which results in the fusion of the AML1 (RUNX1) and ETO (CBFA2T1) genes, is a recurrent aberration in acute myeloid leukemia (AML), preferentially correlated with FAB M2, and has the highest incidence in childhood AML.
|
12557226 |
2003 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CD7+ near-tetraploid acute myeloblastic leukemia M2 with double t(8;21)(q22;q22) translocations and Aml1/ETO rearrangements detected by fluorescence in situ hybridization analysis.
|
11721969 |
2001 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aml1/ETO and Pml/RARA rearrangements in a case of AML-M2 acute myeloblastic leukemia with t(15;17).
|
10221524 |
1999 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The chromosomal translocation t(8;21) (q22;q22) is often associated with acute myeloid leukemia with maturation (AML-M2) and can be detected by a reverse transcription-polymerase chain reaction (RT-PCR) for the AML1/ETO fusion mRNA.
|
9619731 |
1998 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continous clinical remission.
|
7794758 |
1995 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with acute myeloid leukaemia with maturation (AML-M2) that carried the t(8;21) were tested for the presence of chimeric AML1/ETO mRNA.
|
7523801 |
1994 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that RT-PCR amplification of the AML1/ETO fusion transcript is a powerful tool for diagnosing and monitoring minimal residual disease in AML-M2 patients.
|
7507193 |
1994 |